This guidance has been re-issued after a change to the patient access scheme. Recommendation 1.1 of the guidance has been updated (August 2013).

NICE recommends pazopanib as a possible treatment for some people with renal cell carcinoma (see below).

You should be able to have pazopanib if:

  • your renal cell carcinoma is advanced and
  • you have not had treatment for advanced renal cell carcinoma before and
  • you are mobile and can do light housework or office work.

When assessing people with disabilities, healthcare professionals should bear in mind that a person’s disability might also affect their level of physical activity. They should make adjustments for this.

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their lives. NICE recommended pazopanib because it works as well as other treatments available on the NHS, but costs less.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)